- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02428218
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
April 11, 2016 updated by: Biogen
A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis
The primary objective of the study is to assess the efficacy of oral BG00012 as compared with placebo in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS).
The secondary objectives of this study are to evaluate the safety and tolerability of BG00012 and to compare the effect of BG00012 with placebo on additional clinical and radiological measures of disease activity.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Informed consent and assent as appropriate
- Must have a body weight of ≥30 kg
- Must have a diagnosis of RRMS as defined by the revised consensus definition for pediatric multiple sclerosis (MS)
- Must be ambulatory with a converted Krutzke Baseline Expanded Disability Status Scale (EDSS) score between 0 and 5.0, inclusive
Key Exclusion Criteria:
- Primary progressive, secondary progressive, or progressive relapsing MS.
- History of disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease and lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
- History of severe allergic or anaphylactic reactions, or known drug hypersensitivity to dimethyl fumarate (DMF) or fumaric acid esters.
- Prior treatment with any of the following medications within 12 months prior to randomization: mitoxantrone, cyclophosphamide, rituximab.
- Prior treatment with any of the following medications or procedures within 6 months prior to randomization: fingolimod, teriflunomide, natalizumab, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, laquinimod, intravenous (IV) immunoglobulin, plasmapheresis or cytapheresis.
NOTE: Other protocol defined inclusion/exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BG00012
Participants will receive 120 mg capsule(s) BG00012 taken orally.
|
enteric-coated microtablets
Other Names:
|
Experimental: Placebo
Participants will receive matching placebo capsule(s) taken orally.
|
enteric-coated microtablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first multiple sclerosis (MS) relapse
Time Frame: Up to week 104
|
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the Examining Neurologist.
|
Up to week 104
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants that experience adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to week 104
|
Up to week 104
|
Number of new or newly enlarging T2 Hyperintense Lesions on Brain magnetic resonance imaging (MRI) scans
Time Frame: Weeks 24, 48, 72 and 96
|
Weeks 24, 48, 72 and 96
|
Number of gadolinium-enhancing Lesions
Time Frame: Baseline, and weeks 24, 48, 72 and 96
|
Baseline, and weeks 24, 48, 72 and 96
|
Annualized MS relapse rate
Time Frame: weeks 48 and 96
|
weeks 48 and 96
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Anticipated)
January 1, 2027
Study Completion (Anticipated)
January 1, 2027
Study Registration Dates
First Submitted
April 23, 2015
First Submitted That Met QC Criteria
April 23, 2015
First Posted (Estimate)
April 28, 2015
Study Record Updates
Last Update Posted (Estimate)
April 13, 2016
Last Update Submitted That Met QC Criteria
April 11, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Dimethyl Fumarate
Other Study ID Numbers
- 109MS309
- 2014-005624-98 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing-Remitting Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on dimethyl fumarate
-
BiogenCompleted
-
Xuanwu Hospital, BeijingTerminatedAcute Ischemic StrokeChina
-
BiogenCompletedMultiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingFrance
-
Almirall, S.A.Completed
-
Beijing Tiantan HospitalBeijing Chao Yang Hospital; Henan Provincial People's Hospital; Beijing Neurosurgical...Not yet recruitingIntracranial Aneurysm | Aneurysm, Brain | Inflammation VascularChina
-
University at BuffaloCompletedMultiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedMonitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (SURV-SEP)Multiple Sclerosis, Relapsing-RemittingFrance
-
Genesis Pharma CNS & SpecialtyCompleted
-
BiogenCompletedMultiple Sclerosis, Relapsing-RemittingPoland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
-
Banner Life Sciences LLCCompletedMultiple SclerosisUnited States